Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Shannon R. Morris"'
Autor:
Joyce M. Antal, Jennifer L. Gauvin, Carol Aghajanian, Jennifer J. Wheler, Ademi Santiago-Walker, Carla Kurkjian, Joanna Opalinska, Lillian L. Siu, Shubham Pant, Howard A. Burris, Shannon R. Morris, David S. Hong, Lee Ann Stayner, Jeffrey R. Infante, Katherine M. Bell-McGuinn
Publikováno v:
Investigational new drugs. 36(6)
BACKGROUND: We sought to determine the recommended phase II dose (RP2D) and schedule of GSK2141795, an oral pan-AKT kinase inhibitor. PATIENTS AND METHODS: Patients with solid tumors were enrolled in the dose-escalation phase. Pharmacokinetic (PK) an
Autor:
Thomas A. Lampkin, Emily K. Bergsland, Deborah A. Smith, Neeraj Agarwal, Razelle Kurzrock, Ruud van der Noll, Petronella O. Witteveen, Michael Durante, Joseph F. Kleha, Laurel M. Adams, Shannon R. Morris, Rahul Aggarwal, David S. Hong, Pamela N. Munster, E. Claire Dees, Jennifer M. Specht, Theresa L. Werner, Jan H.M. Schellens
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(8)
Purpose: GSK2126458 (GSK458) is a potent inhibitor of PI3K (α, β, γ, and δ), with preclinical studies demonstrating broad antitumor activity. We performed a first-in-human phase I study in patients with advanced solid tumors. Materials and Method
Autor:
Johanna C. Bendell, Ghassan K. Abou-Alfa, Michael A. Morse, Yoon-Koo Kang, Masatoshi Kudo, Joyce Antal, Ann-Lii Cheng, Feng Xiao, Stephen L. Chan, Andrew X. Zhu, Richard D. Kim, Bruno Sangro, Jillian Boice, Shannon R. Morris
Publikováno v:
Journal of Clinical Oncology. 34:TPS3103-TPS3103
TPS3103Background: No approved standard-of-care treatment options exist for patients with unresectable HCC who progress on, are intolerant to, or have refused sorafenib therapy. The PD-1/PD-L1 path...
Autor:
S. Gail Eckhardt, Gerald S. Falchook, Razelle Kurzrock, Carlos Becerra, Howard A. Burris, Keith T. Flaherty, Ngocdiep T. Le, Douglas J. DeMarini, Donna S. Cox, Vijay Gopal Reddy Peddareddigari, Sujatha Nallapareddy, Wells A. Messersmith, Leslie A. Fecher, Michael S. Gordon, Shannon R. Morris, Jeffrey R. Infante, Johanna C. Bendell, Yanmei Xu, Lowell L. Hart
Publikováno v:
The Lancet. Oncology. 13(8)
Summary Background Inhibition of MEK stops cell proliferation and induces apoptosis; therefore, this enzyme is a key anticancer target. Trametinib is a selective, orally administered MEK1/MEK2 inhibitor. We aimed to define the maximum tolerated dose
Autor:
Uday B. Dandamudi, Raymond J. Hohl, Brendan M. Johnson, Lionel D. Lewis, R. Timothy Webb, Laurel M. Adams, Sharon C. Murray, Shannon R. Morris, John W. Bauman, Elaina M. Gartner
Publikováno v:
Cancer chemotherapy and pharmacology. 67(4)
The neurokinin-1 receptor antagonist, casopitant, is a weak-to-moderate inhibitor of cytochrome P450 isoenzyme 3A4 (CYP3A) and has the potential to inhibit the metabolism of CYP3A substrates such as docetaxel.Fourteen cancer patients were enrolled in